Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)
Blood (2014)
  • Joseph G Jurcic, Columbia University Medical Center
  • Farhad Ravandi, University of Texas MD Anderson Cancer Center
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Jae H Park, Memorial Sloan Kettering Cancer Center
  • B. Douglas Smith, Johns Hopkins University
  • Dan Douer, Memorial Sloan Kettering Cancer Center
  • Elihu H. Estey, Fred Hutchinson Cancer Research Center
  • Hagop M. Kantarjian, University of Texas MD Anderson Cancer Center
  • Richard L. Wahl, Johns Hopkins University
  • Dennis Earle
  • Dragan Cicic
  • David A. Scheinberg, Memorial Sloan Kettering Cancer Center
Link
Disciplines
Publication Date
December 6, 2014
Citation Information
Joseph G Jurcic, Farhad Ravandi, John M. Pagel, Jae H Park, et al.. "Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)" Blood Vol. 124 Iss. 21 (2014) p. 5293 - 5293
Available at: http://works.bepress.com/john-pagel/85/